|
GB587992A
(en)
|
1944-12-11 |
1947-05-12 |
Charles William Scaife |
Improvements in and relating to the production of organic nitrogen compounds
|
|
US3578687A
(en)
|
1968-01-30 |
1971-05-11 |
Texaco Inc |
Process for producing 4-nitroalkanoic acids
|
|
US3819561A
(en)
|
1970-10-23 |
1974-06-25 |
Aerojet General Co |
Wetting agents for non-aqueous dispersions
|
|
JPS5313608B2
(pt)
|
1972-06-16 |
1978-05-11 |
|
|
|
JPS5318013B2
(pt)
|
1973-03-19 |
1978-06-13 |
|
|
|
US4599430A
(en)
|
1981-12-21 |
1986-07-08 |
The Standard Oil Company |
Nitrogenation of hydrocarbons, including the production of maleimide
|
|
JPS62132804A
(ja)
|
1985-12-05 |
1987-06-16 |
Aguro Kanesho Kk |
植物生長調節剤
|
|
US5412137A
(en)
|
1993-06-07 |
1995-05-02 |
Sandoz Ltd. |
Process for preparing phosphinyloxy propanaminium inner salt derivatives
|
|
AU2989695A
(en)
|
1994-08-08 |
2000-03-07 |
Debiopharm S.A. |
Pharmaceutically stable oxaliplatinum preparation
|
|
JPH10507179A
(ja)
|
1994-10-13 |
1998-07-14 |
ペプチド テクノロジー リミテッド |
修飾ポリ不飽和脂肪酸
|
|
US5919816A
(en)
|
1994-11-14 |
1999-07-06 |
Bionumerik Pharmaceuticals, Inc. |
Formulations and methods of reducing toxicity of antineoplastic agents
|
|
US5741211A
(en)
|
1995-10-26 |
1998-04-21 |
Medtronic, Inc. |
System and method for continuous monitoring of diabetes-related blood constituents
|
|
GB9618420D0
(en)
|
1996-09-04 |
1996-10-16 |
Scotia Holdings Plc |
Fatty acid treatment
|
|
US6187747B1
(en)
|
1997-09-08 |
2001-02-13 |
Panacea Biotech Limited |
Pharmaceutical composition comprising cyclosporin
|
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
|
US6531150B1
(en)
|
1997-10-30 |
2003-03-11 |
Morishita Jintan Co., Ltd. |
Encapsulated unsaturated fatty acid substance and method for producing the same
|
|
CA2395558C
(en)
|
1997-11-12 |
2007-07-17 |
Bayer Aktiengesellschaft |
Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
|
|
US7795246B2
(en)
|
1998-08-06 |
2010-09-14 |
Cephalon, Inc. |
Particle-forming compositions containing fused pyrrolocarbazoles
|
|
WO2000009075A2
(en)
|
1998-08-14 |
2000-02-24 |
Galenica Pharmaceuticals, Inc. |
Chemically modified saponins and the use thereof as adjuvants
|
|
IL144156A0
(en)
|
1999-01-20 |
2002-05-23 |
Dresden Arzneimittel |
Use of imidazo [1,5-a]-pyrido [3,2-e] -pyrazinones as medicaments
|
|
US6410802B1
(en)
|
1999-04-01 |
2002-06-25 |
Esperion Therapeutics, Inc. |
Methods for synthesizing ether compounds and intermediates therefor
|
|
AU5319499A
(en)
|
1999-07-22 |
2001-02-13 |
Ivan L. Cameron |
Fatty acids to minimize cancer therapy side effects
|
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
|
AUPQ291499A0
(en)
|
1999-09-17 |
1999-10-07 |
Women's And Children's Hospital Adelaide |
Novel nitro and sulphur containing compounds
|
|
US6346231B1
(en)
|
1999-10-06 |
2002-02-12 |
Joar Opheim |
Flavored gelatin capsule and method of manufacture
|
|
IL139457A0
(en)
|
1999-11-08 |
2001-11-25 |
Pfizer |
Compounds for the treatment of female sexual dysfunction
|
|
US20010037598A1
(en)
|
1999-12-14 |
2001-11-08 |
Suppes Galen J. |
Process for producing cetane improvers from triglycerides
|
|
EP1762557B1
(en)
|
2000-02-16 |
2011-04-06 |
The Brigham And Women's Hospital, Inc. |
Aspirin-triggered lipid mediators
|
|
AR030416A1
(es)
|
2000-04-13 |
2003-08-20 |
Pharmacia Corp |
COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
|
|
AR032318A1
(es)
|
2000-04-13 |
2003-11-05 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
|
|
AR034120A1
(es)
|
2000-04-13 |
2004-02-04 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
|
|
EP1294658B1
(en)
|
2000-06-28 |
2005-03-02 |
ZAMBON GROUP S.p.A. |
Process for the preparation of nitroalkenes
|
|
AR031129A1
(es)
|
2000-09-15 |
2003-09-10 |
Pharmacia Corp |
Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
|
|
DE20221679U1
(de)
|
2001-03-02 |
2006-11-23 |
Debiopharm S.A. |
Vorrichtung zur Konditionierung einer Oxaliplatinlösung
|
|
JP5026655B2
(ja)
|
2001-04-18 |
2012-09-12 |
プロメティック、バイオサイエンシーズ、インコーポレーテッド |
好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
|
|
US7105556B2
(en)
|
2001-05-30 |
2006-09-12 |
Bristol-Myers Squibb Company |
Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
|
|
EP1407767A4
(en)
|
2001-06-18 |
2007-01-24 |
Yamada Sachiko |
AGONIST MEDICINAL PREPARATIONS PPAR $ G (G)
|
|
EP1418876A4
(en)
|
2001-08-17 |
2007-07-11 |
Univ Pittsburgh |
ADMINISTRATION OF OSTRADIOL METABOLITES FOR THE TREATMENT OR PREVENTION OF ADIPOSITAS, METABOLIC SYNDROME, DIABETES AND VASCULAR AND KIDNEY DISEASES
|
|
GB0123961D0
(en)
|
2001-10-05 |
2001-11-28 |
Astrazeneca Ab |
Process and intermediates
|
|
JP2005508978A
(ja)
|
2001-11-02 |
2005-04-07 |
ファイザー・プロダクツ・インク |
Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
|
|
HN2002000317A
(es)
|
2001-11-02 |
2003-05-21 |
Pfizer |
Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
|
|
US20030166716A1
(en)
|
2001-11-06 |
2003-09-04 |
Serhan Charles N. |
Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
|
|
GB2388111A
(en)
|
2002-05-01 |
2003-11-05 |
Bayer Ag |
Novel imidazotriazinone compounds
|
|
US6684626B1
(en)
|
2002-07-30 |
2004-02-03 |
General Electric Company |
Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
|
|
US7759395B2
(en)
|
2002-08-12 |
2010-07-20 |
The Brigham And Women's Hospital, Inc. |
Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
|
|
CA2875522A1
(en)
|
2002-08-20 |
2004-03-04 |
Philera New Zealand Limited |
Dosage forms and related therapies
|
|
EP2384750A1
(en)
|
2002-09-27 |
2011-11-09 |
Martek Biosciences Corporation |
Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
|
|
WO2004037311A2
(en)
|
2002-10-21 |
2004-05-06 |
Kensey Nash Corporation |
Device and methods for sequential, regional delivery of multiple cytotoxic agents
|
|
US7166575B2
(en)
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
|
US20040220186A1
(en)
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
|
WO2005016864A1
(en)
|
2003-07-29 |
2005-02-24 |
The Arizona Disease Control Research Commission |
Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
|
|
US20050136103A1
(en)
|
2003-09-17 |
2005-06-23 |
Ben-Sasson Shmuel A. |
Compositions capable of facilitating penetration across a biological barrier
|
|
US7935365B2
(en)
|
2003-10-22 |
2011-05-03 |
Enzymotec, Ltd. |
Glycerophospholipids for the improvement of cognitive functions
|
|
WO2005041972A1
(en)
|
2003-10-31 |
2005-05-12 |
Pfizer Products Inc. |
Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
|
|
US20090215895A1
(en)
|
2004-01-30 |
2009-08-27 |
Peplin Biolipids Pty Ltd |
Therapeutic and carrier molecules
|
|
CA2563533C
(en)
|
2004-04-15 |
2013-10-01 |
Shmuel A. Ben-Sasson |
Compositions capable of facilitating penetration across a biological barrier
|
|
US7776916B2
(en)
|
2004-04-28 |
2010-08-17 |
The Uab Research Foundation |
Nitrated lipids and methods of making and using thereof
|
|
RU2527893C2
(ru)
|
2004-07-19 |
2014-09-10 |
Биокон Лимитед |
Инсулин-олигомерные конъюгаты, их препараты и применения
|
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
|
EP1772149A1
(en)
|
2004-07-27 |
2007-04-11 |
Kowa Company. Ltd. |
Drug for prevention or treatment of diabetes
|
|
BRPI0516803A
(pt)
|
2004-11-19 |
2008-09-23 |
Martek Biosciences Corp |
oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
|
|
WO2006058250A2
(en)
|
2004-11-24 |
2006-06-01 |
Spi Pharma, Inc. |
Orally disintegrating compositions
|
|
AU2011202664B2
(en)
|
2004-12-08 |
2012-04-05 |
Cedars-Sinai Medical Center |
Methods for diagnosis and treatment of Crohn's disease
|
|
WO2006086727A2
(en)
|
2005-02-09 |
2006-08-17 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
|
JP2009507032A
(ja)
|
2005-09-02 |
2009-02-19 |
アボット・ラボラトリーズ |
新規なイミダゾ系複素環
|
|
GB0522569D0
(en)
|
2005-11-04 |
2005-12-14 |
Univ Bath |
Biocompatible drug delivery device
|
|
TW200815436A
(en)
|
2006-05-30 |
2008-04-01 |
Elbion Ag |
4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
|
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
|
WO2008008767A2
(en)
|
2006-07-14 |
2008-01-17 |
Cedars-Sinai Medical Center |
Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer
|
|
MX2009000657A
(es)
|
2006-07-19 |
2009-05-28 |
Resolvyx Pharmaceuticals Inc |
Composiciones y metodos para el tratamiento de mucositis.
|
|
EP2123801A4
(en)
|
2006-09-08 |
2011-01-19 |
Tokuyama Corp |
METHOD AND DEVICE FOR PREPARING GROUP III NITRIDE
|
|
WO2008072778A1
(ja)
*
|
2006-12-13 |
2008-06-19 |
Aska Pharmaceutical Co., Ltd. |
尿路系疾患の処置剤
|
|
US8299080B2
(en)
|
2006-12-13 |
2012-10-30 |
Aska Pharmaceutical Co., Ltd. |
Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
|
|
WO2008103753A2
(en)
|
2007-02-20 |
2008-08-28 |
Martek Biosciences Corporation |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
|
RS52166B
(sr)
|
2007-05-11 |
2012-08-31 |
Pfizer Inc. |
Amino-heterociklična jedinjenja
|
|
DE102007032349A1
(de)
|
2007-07-11 |
2009-01-15 |
Bayer Healthcare Ag |
Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
|
|
WO2009017802A1
(en)
|
2007-08-01 |
2009-02-05 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Nitro-fattyacid modulation of type ii diabetes
|
|
CA2699483A1
(en)
|
2007-09-14 |
2009-03-26 |
Resolvyx Pharmaceuticals, Inc. |
Compositions and methods for modulating immune function
|
|
WO2009129495A1
(en)
|
2008-04-18 |
2009-10-22 |
The University Of Utah Research Foundation |
Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
|
|
JP2011519373A
(ja)
|
2008-05-01 |
2011-07-07 |
コンプレクザ インコーポレイテッド |
ビニル置換脂肪酸
|
|
WO2009149496A1
(en)
|
2008-06-10 |
2009-12-17 |
Central Northern Adelaide Health Service |
Treatment of diabetes and complications thereof and related disorders
|
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
|
EP2299997A4
(en)
|
2008-06-19 |
2012-01-11 |
Univ Utah Res Found |
USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
|
|
EP2320903B1
(en)
|
2008-07-29 |
2017-01-18 |
Nerviano Medical Sciences S.r.l. |
THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
|
|
CA2740000C
(en)
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
US8933255B2
(en)
|
2008-12-31 |
2015-01-13 |
Nitromega Corp. |
Nutraceuticals containing nitro fatty acids
|
|
US8937194B2
(en)
|
2008-12-31 |
2015-01-20 |
Nitromega Corp. |
Topical compositions containing nitro fatty acids
|
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基－雜環化合物
|
|
US20100286271A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Nitro-alkyl Compound Compositions
|
|
US20100286272A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
|
|
US20100286257A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
|
|
WO2011011712A1
(en)
|
2009-07-24 |
2011-01-27 |
Concert Pharmaceuticals, Inc. |
Substituted imidazotriazines
|
|
JP2013500275A
(ja)
|
2009-07-29 |
2013-01-07 |
フェノメノーム ディスカバリーズ インク |
ヒドロキシ脂肪酸化合物並びに疾患治療及び診断のためのその使用
|
|
EP3045167A1
(en)
|
2009-07-31 |
2016-07-20 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Keto fatty acids as anti-inflammatory agents
|
|
WO2011028820A1
(en)
|
2009-09-02 |
2011-03-10 |
Concert Pharmaceuticals, Inc. |
Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
|
|
WO2011030351A2
(en)
|
2009-09-03 |
2011-03-17 |
Rubicon Research Private Limited |
Taste - masked pharmaceutical compositions
|
|
EP2483233A4
(en)
|
2009-10-02 |
2013-08-14 |
Complexa Inc |
HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
|
|
CA2777455A1
(en)
|
2009-11-09 |
2011-05-12 |
Novadex Pharmaceuticals Ab |
Novel 1,3-oxazolidine compounds and their use as renin inhibitors
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
KR20130054249A
(ko)
|
2010-03-15 |
2013-05-24 |
울리히 디에츠 |
공격적 치료 패턴의 치료, 진단 및 예방용 니트로카르복실산의 용도
|
|
EP2568826A4
(en)
|
2010-05-13 |
2014-03-26 |
Nitromega Corp |
NITRATED FATTY ACIDS, NEUROPROTECTION AND / OR INHIBITION OF COGNITIVE DECLINE
|
|
US20110319325A1
(en)
|
2010-06-28 |
2011-12-29 |
Complexa, Inc. |
Multi-component pharmaceuticals for treating diabetes
|
|
EP2619208B1
(en)
|
2010-09-20 |
2016-11-09 |
Ironwood Pharmaceuticals, Inc. |
Imidazotriazinone compounds
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
WO2013028501A1
(en)
|
2011-08-19 |
2013-02-28 |
The University Of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
|
JO3116B1
(ar)
|
2011-10-07 |
2017-09-20 |
Eisai R&D Man Co Ltd |
مشتق بيرازولوكينولين كمثبطات ل pde9
|
|
BR112015007731B1
(pt)
|
2011-10-10 |
2022-05-31 |
H. Lundbeck A/S |
Composto, composição farmacêutica que o compreende e uso do mesmo
|
|
US9271952B2
(en)
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
|
DE102012008730A1
(de)
|
2011-12-02 |
2013-06-06 |
Dr. Budz GmbH |
Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
|
|
BR112014018199A8
(pt)
|
2012-01-26 |
2021-03-02 |
H Lundbeck As |
inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
|
|
ES2681027T3
(es)
|
2012-02-01 |
2018-09-11 |
City Of Hope |
Inhibidores de la ribonucleótida reductasa y métodos de uso
|
|
WO2013116753A1
(en)
|
2012-02-03 |
2013-08-08 |
University Of Pittsburgh-Of The Commonwelth System Of Higher Education |
Fatty acids as anti-inflammatory agents
|
|
US10435367B2
(en)
|
2013-03-14 |
2019-10-08 |
City Of Hope |
Indirubin derivatives, and uses thereof
|
|
HK1206726A1
(en)
|
2012-03-19 |
2016-01-15 |
Ironwood Pharmaceuticals, Inc. |
Imidazotriazinone compounds
|
|
WO2013170069A1
(en)
|
2012-05-09 |
2013-11-14 |
Massachusetts Institute Of Technology |
Medicament, method, and drug delivery device for treatment of ovarian cancer
|
|
JP6463266B2
(ja)
|
2012-08-31 |
2019-01-30 |
タリス バイオメディカル エルエルシー |
膀胱癌の治療のためのオキサリプラチンを含む薬物送達システム及び方法
|
|
US20140271844A1
(en)
|
2013-03-15 |
2014-09-18 |
Nitromega Corp. |
Compositions containing nitro fatty acids
|
|
WO2014169137A1
(en)
|
2013-04-10 |
2014-10-16 |
Massachusetts Institute Of Technology |
Local drug delivery devices and methods for treating cancer
|
|
CN105339006A
(zh)
|
2013-05-10 |
2016-02-17 |
尼特罗米加公司 |
含有脂肪酸和亚硝酸盐的营养或膳食补充剂
|
|
US20150051283A1
(en)
|
2013-06-14 |
2015-02-19 |
Complexa, Inc. |
Composition and method for inhibition of pkng from mycobacterium tuberculosis
|
|
US10369340B2
(en)
|
2013-08-12 |
2019-08-06 |
Nanomedical Systems, Inc. |
Device and method for sustained release of low water solubility therapeutic agent in solubilizer
|
|
WO2015073527A1
(en)
|
2013-11-12 |
2015-05-21 |
Complexa, Inc. |
Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
|
|
WO2015185499A1
(en)
|
2014-06-06 |
2015-12-10 |
H. Lundbeck A/S |
Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
|
|
EP3194386A2
(en)
|
2014-09-17 |
2017-07-26 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
|
WO2016161285A1
(en)
|
2015-04-02 |
2016-10-06 |
Aobiome Llc |
Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
|
|
PT3865484T
(pt)
|
2015-07-07 |
2024-01-30 |
H Lundbeck As |
Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas
|
|
WO2017059451A1
(en)
|
2015-10-02 |
2017-04-06 |
Complexa, Inc. |
Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
|
|
MX376974B
(es)
|
2016-02-19 |
2025-03-07 |
Phoenix Molecular Designs |
Derivados de carboxamida útiles como inhibidores de rsk.
|
|
MX2018016127A
(es)
|
2016-07-06 |
2019-05-30 |
Imara Inc |
Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
|
|
CN115746003B
(zh)
|
2017-05-26 |
2024-08-09 |
卡都瑞恩医药公司 |
制备和使用pde9抑制剂的方法
|
|
CA3100988A1
(en)
|
2018-05-25 |
2019-11-28 |
Imara Inc. |
Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
|
|
CA3110680A1
(en)
|
2018-08-31 |
2020-03-05 |
Imara Inc. |
Pde9 inhibitors for treating sickle cell disease
|
|
EP3946348A4
(en)
|
2019-04-05 |
2023-08-02 |
Imara Inc. |
PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
|
|
EP3965768A1
(en)
|
2019-05-07 |
2022-03-16 |
Imara Inc. |
Pde9 inhibitors for treating thalassemia
|
|
WO2022036111A1
(en)
|
2020-08-13 |
2022-02-17 |
Imara Inc. |
Methods and compositions for treating sickle cell disease
|
|
US20240025904A1
(en)
|
2020-10-27 |
2024-01-25 |
Cardurion Pharmaceuticals, Inc. |
Pde9 inhibitors for treating cardiac failure
|